ADC Therapeutics SA (ADCT)
ADC Therapeutics SA (ADCT) is a clinical-stage biotechnology company specializing in the development of antibody-drug conjugates (ADCs) for the treatment of hematologic and solid tumors. Founded in Switzerland, the company focuses on targeted cancer therapies designed to deliver cytotoxic agents directly to cancer cells, minimizing damage to healthy tissue. Its pipeline includes multiple ADCs in various stages of clinical development, aiming to address unmet medical needs in oncology.
Company News
Analysts forecast the global oncology drug market to exceed $900 billion by 2034, with biotech firms like Oncolytics, Teva, Citius, ADC Therapeutics, and OS Therapies driving cancer treatment innovation amid potential NCI funding cuts.
The blood cancer market is experiencing robust growth, driven by rising incidence rates and advancements in targeted therapies and immuno-oncology. Increasing adoption of CAR-T cell therapies, monoclonal antibodies, and personalized medicine is transforming treatment outcomes.
ADC Therapeutics (ADCT) delivered earnings and revenue surprises of 0% and 0.75%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
ADCT earnings call for the period ending June 30, 2022.